Literature DB >> 9507911

Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect.

L Ranganath1, F Norris, L Morgan, J Wright, V Marks.   

Abstract

The therapeutic effect of acarbose is generally attributed to inhibition of amylase and brush border glucosidases and consequent impaired digestion and absorption of carbohydrates. We have investigated the possibility that acarbose may also influence the rate of gastric emptying by comparing plasma glucose and gastrointestinal hormone responses to an oral sucrose load with and without acarbose in 11 healthy subjects. Gastric emptying was assessed indirectly by measuring circulating paracetamol concentrations following administration of paracetamol along with the sucrose load. Peak plasma glucose, insulin, and glucose-dependent insulinotropic polypeptide (GIP) responses were reduced when sucrose was given with acarbose. There was a significant reduction in post-sucrose paracetamol levels with acarbose suggestive of a significant delay in gastric emptying. The failure of acarbose to induce change in circulating paracetamol concentrations until after 60 min is indicative of a delay in gastric emptying rather than an osmotic malabsorption. The exaggerated and sustained release of glucagon-like peptide-1 (7-36)amide (GLP-1) seen when sucrose was given with acarbose may play a part in the inhibition of gastric emptying. This study indicates that a significant delay in gastric emptying may be an added mechanism contributing to the therapeutic effect of acarbose.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507911     DOI: 10.1002/(SICI)1096-9136(199802)15:2<120::AID-DIA529>3.0.CO;2-I

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  18 in total

1.  Erythritol reduces small intestinal glucose absorption, increases muscle glucose uptake, improves glucose metabolic enzymes activities and increases expression of Glut-4 and IRS-1 in type 2 diabetic rats.

Authors:  Chika Ifeanyi Chukwuma; Ramgopal Mopuri; Savania Nagiah; Anil Amichund Chuturgoon; Md Shahidul Islam
Journal:  Eur J Nutr       Date:  2017-08-02       Impact factor: 5.614

Review 2.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  Postprandial hypotension treated with acarbose in a patient with type 1 diabetes mellitus.

Authors:  Simona Maule; Mirko Tredici; Antonio Dematteis; Cristina Matteoda; Livio Chiandussi
Journal:  Clin Auton Res       Date:  2004-12       Impact factor: 4.435

4.  Incretin secretion in humans is under the influence of cannabinoid receptors.

Authors:  Chee W Chia; Olga D Carlson; David D Liu; Isabel González-Mariscal; Sara Santa-Cruz Calvo; Josephine M Egan
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-06-27       Impact factor: 4.310

5.  Long-term treatment with acarbose for the treatment of reactive hypoglycemia.

Authors:  A G Ozgen; F Hamulu; F Bayraktar; S Cetínkalp; C Yilmaz; M Túzún; T Kabalak
Journal:  Eat Weight Disord       Date:  1998-09       Impact factor: 4.652

6.  Inhibition of small-intestinal sugar absorption mediated by sodium orthovanadate Na3VO4 in rats and its mechanisms.

Authors:  Jing Ai; Jie Du; Ning Wang; Zhi-Min Du; Bao-Feng Yang
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

7.  OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself.

Authors:  Katrin Hücking; Richard M Watanabe; Darko Stefanovski; Richard N Bergman
Journal:  Obesity (Silver Spring)       Date:  2008-07-10       Impact factor: 5.002

8.  Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: a dual approach study.

Authors:  Chika Ifeanyi Chukwuma; Mohammed Auwal Ibrahim; Md Shahidul Islam
Journal:  J Physiol Biochem       Date:  2016-09-06       Impact factor: 4.158

9.  Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy.

Authors:  Takeshi Fukushima; Masato Asahina; Yoshikatsu Fujinuma; Yoshitaka Yamanaka; Akira Katagiri; Masahiro Mori; Satoshi Kuwabara
Journal:  J Neurol       Date:  2012-09-15       Impact factor: 4.849

Review 10.  Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?

Authors:  Guillaume Charpentier; Jean-Pierre Riveline; Dured Dardari; Michel Varroud-Vial
Journal:  Drugs       Date:  2006       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.